ArticleEuropean urology open science2025

Ultralow Prostate-specific Antigen Nadir After Apalutamide: Outcomes in Synchronous Versus Metachronous Metastatic Hormone-sensitive Prostate Cancer.

Mike Wenzel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.